Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TScan TherapeuticsTCRX -8.69%44 Equity-to-Asset is 0.40 as of Jun. 2026, which is 30% below its 10-year median of 0.57. GuruFocus rates TCRX with a GF Score™ of 44/100 and a GF Value™ of $1.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,414 Biotechnology companies, TScan Therapeutics ranks worse than 73.2% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. TScan Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $69.02 Mil. TScan Therapeutics's Total Assets for the quarter that ended in Jun. 2026 was $171.45 Mil.
Therefore, TScan Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.40.
The historical rank and industry rank for TScan Therapeutics's Equity-to-Asset or its related term are showing as below:
TCRX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.85 Med: 0.57 Max: 0.87
Current: 0.4
During the past 7 years, the highest Equity to Asset Ratio of TScan Therapeutics was 0.87. The lowest was -0.85. And the median was 0.57.
TCRX's Equity-to-Asset is ranked worse than 73.2% of 1414
companies
in the Biotechnology industry
Industry Median: 0.69
vs TCRX: 0.40
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
TScan Therapeutics Equity-to-Asset Related Terms
TScan Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for TScan Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCRX vs MCRB, HYPD, ELOX: Equity-to-Asset Comparison
For the Biotechnology subindustry, TScan Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TScan Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where TScan Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
TScan Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TScan Therapeutics (TCRX) has a Equity-to-Asset of 0.40 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on TScan Therapeutics and its competitors. This is 30% below median its historical median of 0.57. According to the industry distribution chart, TScan Therapeutics ranks #1035 out of 1414 companies in the Biotechnology industry, placing it in the top 73.2%.
Is TScan Therapeutics' Equity-to-Asset too high?
TScan Therapeutics' current Equity-to-Asset of 0.40 is 30% below median its 10-year median of 0.57. The Biotechnology industry median Equity-to-Asset is 0.69. TScan Therapeutics' value of 0.40 is 42% below this industry median. Based on the distribution chart, TScan Therapeutics ranks #1035 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' Equity-to-Asset compare to MCRB and HYPD?
According to the Biotechnology industry distribution chart, TScan Therapeutics ranks #1035 out of 1414 companies for Equity-to-Asset. This places TScan Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.69. TScan Therapeutics' value of 0.40 is 42% below this benchmark. While the company's 10-year median is 0.57 vs. the industry median of 0.69, TScan Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TScan Therapeutics's current Equity-to-Asset of 0.40 is 42% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on TScan Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TScan Therapeutics's current Equity-to-Asset is 0.40, which is 30% below median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.67 — trading 49.6% below its estimated fair value. The current Equity-to-Asset is 0.40, which is 30% below median its 10-year median of 0.57 and 42% below the Biotechnology industry median of 0.69. TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current Equity-to-Asset is 0.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TScan Therapeutics (TCRX) Overvalued in 2026?
Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued.
The current stock price of $0.67 is trading 49.6% below its estimated GF Value™ of $1.32.
GuruFocus considers TScan Therapeutics to be Possible Value Trap.
Key valuation signals for TCRX:
Equity-to-Asset: 0.40 (30% below median its 10-year median of 0.57)
GF Value™: $1.32 vs. price of $0.67 (49.6% below fair value)
Industry Position: 42% below the Biotechnology median (#1035 of 1414)
No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score
Get the complete analysis for TCRX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRX has been successfully added to your 
